γ-oryzanol reduces caveolin-1 and PCGEM1 expression, markers of aggressiveness in prostate cancer cell lines

Prostate

Volumn 75, Issue 8, 2015, Pages 783-797

  Hirsch, Gabriela E ^a   Parisi, Mariana M ^a   Martins, Leo A M ^a   Andrade, Claudia M B ^b   Barbé Tuana, Florencia M ^a   Guma, Fátima T C R ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b Universidade de Mato Grosso   (Brazil)

Author keywords

androgen resistance; metastasis; prostate cancer cell lines; survival genes; oryzanol

Indexed keywords

ANDROGEN; CAVEOLIN 1; GAMMA ORYZANOL; MITOGEN ACTIVATED PROTEIN KINASE; SULFORHODAMINE B; TUMOR MARKER; CAV1 PROTEIN, HUMAN; GAMMA-ORYZANOL; LONG UNTRANSLATED RNA; PCGEM1 NON-CODING RNA, HUMAN; PHENYLPROPIONIC ACID DERIVATIVE;

APOPTOSIS; ARTICLE; BIOMASS; CELL CULTURE; CELL CYCLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL VIABILITY; CONFOCAL MICROSCOPY; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; GENE; GENE EXPRESSION; GENETICS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LNCAP CELL LINE; MALE; NECROSIS; PCGEM1 GENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PROSTATIC NEOPLASMS; TUMOR CELL LINE;

APOPTOSIS; CAVEOLIN 1; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHENYLPROPIONATES; PROSTATIC NEOPLASMS; RNA, LONG NONCODING;

EID: 84927913418     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22960     Document Type: Article

References (87)

1. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Jr., Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI,. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364 (21): 1995-2005.
2. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS,. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367 (13): 1187-1197.
3. West TA, Kiely BE, Stockler MR,. Estimating scenarios for survival time in men starting systemic therapies for castration-resistant prostate cancer: A systematic review of randomised trials. Eur J Cancer 2014; 50: (11)-1924.
4. Kirby M, Hirst C, Crawford ED,. Characterising the castration-resistant prostate cancer population: A systematic review. Int J Clin Pract 2011; 65 (11): 1180-1192.
5. Pienta KJ, Bradley D,. Mechanisms underlying the development of androgen-independent prostate cancer. Clin Cancer Res 2006; 12 (6): 1665-1671.
6. Feldman BJ, Feldman D,. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001; 1 (1): 34-45.
7. Bonkhoff H, Berges R,. From pathogenesis to prevention of castration resistant prostate cancer. Prostate 2010; 70 (1): 100-112.
8. Mahler C, Denis L,. Management of relapsing disease in prostate-cancer. Cancer 1992; 70 (1): 329-334.
9. Brasil MdAd. Ministério da Agricultura do Brasil. 2014.
10. Parrado J, Miramontes E, Jover M, Gutierrez JF, Terán LC, Bautista J,. Preparation of a rice bran enzymatic extract with potential use as functional food. Food Chem 2006; 98: 742-748.
11. Chotimarkorn C, Benjakul S, Silalai N,. Antioxidant components and proprieties of five long-grained rice bran extracts from commercial available cultivars in Thailand. Food Chem 2008; 111 (3): 636-641.
12. Lopes MMA, Miranda MRA, Moura CFH, Filho JE,. Bioactive compounds and total antioxidant capacity of cashew apples (Anacardium occidentale L.) during the ripening of early dwarf cashew clones. Ciência e Agrotecnologia 2012; 36 (3): 325-332.
13. Revilla E, Santa-María C, Miramontes E, Candiracci M, Rodríguez-Morgado B, Carballo M, Bautista J, Castaño A, Parrado J,. Antiproliferative and immunoactivatory ability of an enzymatic extract from rice bran. Food Chem 2013; 136 (2): 526-531.
14. Awad AB, Fink CS,. Phytosterols as anticancer dietary components: Evidence and mechanism of action. J Nutr 2000; 130 (9): 2127-2130.
15. Awad AB, Fink CS, Williams H, Kim U,. In vitro and in vivo (SCID mice) effects of phytosterols on the growth and dissemination of human prostate cancer PC-3 cells. Eur J Cancer Prev 2001; 10 (6): 507-513.
16. von Holtz RL, Fink CS, Awad AB,. β-sitosterol activates the sphingomyelin cycle and induces apoptosis in LNCaP human prostate cancer cells. Nutr Cancer 1998; 32 (1): 8-12.
17. Yang G, Truong LD, Wheeler TM, Thompson TC,. Caveolin-1 expression in clinically confined human prostate cancer: A novel prognostic marker. Cancer Res 1999; 59 (22): 5719-5723.
18. Ifere GO, Barr E, Equan A, Gordon K, Singh UP, Chaudhary J, Igietseme JU, Ananaba GA,. Differential effects of cholesterol and phytosterols on cell proliferation, apoptosis and expression of a prostate specific gene in prostate cancer cell lines. Cancer Detect Prev 2009; 32 (4): 319-328.
19. Razandi M, Alton G, Pedram A, Ghonshani S, Webb P, Levin ER,. Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane. Mol Cell Biol 2003; 23 (5): 1633-1646.
20. Lu ML, Schneider MC, Zheng Y, Zhang X, Richie JP,. Caveolin-1 interacts with androgen receptor. A positive modulator of androgen receptor mediated transactivation. J Biol Chem 2001; 276 (16): 13442-13451.
21. Daniel EE, El-Yazbi A, Cho WJ,. Caveolae and calcium handling, a review and a hypothesis. J Cell Mol Med 2006; 10 (2): 529-544.
22. Freeman M, Yang W, Vizio D,. Caveolin-1 and prostate cancer progression. In:, Jasmin J-F, Frank P, Lisanti M, editors. Caveolins and caveolae. Volume 729, Advances in Experimental Medicine and Biology. USA: Springer. 2012. pp 95-110.
23. Petrovics G, Zhang W, Makarem M, Street JP, Connelly R, Sun L, Sesterhenn IA, Srikantan V, Moul JW, Srivastava S,. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004; 23 (2): 605-611.
24. Fu X, Ravindranath L, Tran N, Petrovics G, Srivastava S,. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene PCGEM1. DNA Cell Biol 2006; 25 (3): 135-141.
25. Kenji M,. Production of oryzanol solubilized in water. Japan 1985.
26. Awad AB, Williams H, Fink CS,. Effect of phytosterols on cholesterol metabolism and MAP kinase in MDA-MB-231 human breast cancer cells. J Nutr Biochem 2003; 14 (2): 111-119.
27. Greenberg-Ofrath N, Terespolosky Y, Kahane I, Bar R,. Cyclodextrins as carriers of cholesterol and fatty acids in cultivation of mycoplasmas. Appl Environ Microbiol 1993; 59 (2): 547-551.
28. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65 (1-2): 55-63.
29. Stockert JC, Blazquez-Castro A, Canete M, Horobin RW, Villanueva A,. MTT assay for cell viability: Intracellular localization of the formazan product is in lipid droplets. Acta Histochem 2012; 114 (8): 785-796.
30. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR,. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82 (13): 1107-1112.
31. Strober W,. Trypan blue exclusion test of cell viability. Curr Protoc Immunol 2001. Appendix 3:Appendix 3B.
32. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25 (4): 402-408.
33. Gomes FC, Paulin D, Moura Neto V,. Glial fibrillary acidic protein (GFAP): Modulation by growth factors and its implication in astrocyte differentiation. Braz J Med Biol Res 1999; 32 (5): 619-631.
34. Thompson TC, Timme TL, Li L, Goltsov A,. Caveolin-1, a metastasis-related gene that promotes cell survival in prostate cancer. Apoptosis 1999; 4 (4): 233-237.
35. INCA. 2013.
36. INCA. 2014.
37. Berges RR, Furuya Y, Remington L, English HF, Jacks T, Isaacs JT,. Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation. Proc Natl Acad Sci USA 1993; 90 (19): 8910-8914.
38. Mukhopadhyay A, Bueso-Ramos C, Chatterjee D, Pantazis P, Aggarwal BB,. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001; 20 (52): 7597-7609.
39. Craft N, Chhor C, Tran C, Belldegrun A, DeKernion J, Witte ON, Said J, Reiter RE, Sawyers CL,. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res 1999; 59 (19): 5030-5036.
40. Ng SS, Figg WD,. Antitumor activity of herbal supplements in human prostate cancer xenografts implanted in immunodeficient mice. Anticancer Res 2003; 23 (5A): 3585-3590.
41. Henderson AJ, Ollila CA, Kumar A, Borresen EC, Raina K, Agarwal R, Ryan EP,. Chemopreventive properties of dietary rice bran: Current status and future prospects. Adv Nutr 2012; 3 (5): 643-653.
42. Evan GI, Vousden KH,. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411 (6835): 342-348.
43. Lowe SW, Lin AW,. Apoptosis in cancer. Carcinogenesis 2000; 21 (3): 485-495.
44. Brown JM, Attardi LD,. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005; 5 (3): 231-237.
45. Edinger AL, Thompson CB,. Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol 2004; 16 (6): 663-669.
46. Okada M, Adachi S, Imai T, Watanabe K, Toyokuni SY, Ueno M, Zervos AS, Kroemer G, Nakahata T,. A novel mechanism for imatinib mesylate-induced cell death of BCR-ABL-positive human leukemic cells: Caspase-independent, necrosis-like programmed cell death mediated by serine protease activity. Blood 2004; 103 (6): 2299-2307.
47. Deng X, He G, Liu J, Luo F, Peng X, Tang S, Gao Z, Lin Q, Keller JM, Yang T, Keller ET,. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat Rev 2014; 40 (6): 730-738.
48. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F,. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev 2014; 40 (1): 3-11.
49. Coleman RE,. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12 (20 Pt 2): 6243s-6249s.
50. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL,. Metastatic patterns in adenocarcinoma. Cancer 2006; 106 (7): 1624-1633.
51. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA,. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339 (15): 1036-1042.
52. Scott WW, Menon M, Walsh PC,. Hormonal-therapy of prostatic-cancer. Cancer 1980; 45: (7):-1936.
53. Damiens E, Baratte B, Marie D, Eisenbrand G, Meijer L,. Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: Induction of endoreplication following prophase arrest. Oncogene 2001; 20 (29): 3786-3797.
54. Soni R, O'Reilly T, Furet P, Muller L, Stephan C, Zumstein-Mecker S, Fretz H, Fabbro D, Chaudhuri B,. Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4. J Natl Cancer Inst 2001; 93 (6): 436-446.
55. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI,. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8 (4): 1168-1171.
56. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin IE, Liotta LA,. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001; 20: (16):-(1989.
57. Ghosh PM, Malik S, Bedolla R, Kreisberg JI,. Akt in prostate cancer: Possible role in androgen-independence. Curr Drug Metab 2003; 4 (6): 487-496.
58. Albrecht DS, Clubbs EA, Ferruzzi M, Bomser JA,. Epigallocatechin-3-gallate (EGCG) inhibits PC-3 prostate cancer cell proliferation via MEK-independent ERK1/2 activation. Chem Biol Interact 2008; 171 (1): 89-95.
59. Agarwal R,. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000; 60 (8): 1051-1059.
60. Xiao D, Singh SV,. Phenethyl isothiocyanate-induced apoptosis in p53-deficient PC-3 human prostate cancer cell line is mediated by extracellular signal-regulated kinases. Cancer Res 2002; 62 (13): 3615-3619.
61. Sarfaraz S, Afaq F, Adhami VM, Malik A, Mukhtar H,. Cannabinoid receptor agonist-induced apoptosis of human prostate cancer cells LNCaP proceeds through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem 2006; 281 (51): 39480-39491.
62. Kitanaka C, Kuchino Y,. Caspase-independent programmed cell death with necrotic morphology. Cell Death Differ 1999; 6 (6): 508-515.
63. Riedl SJ, Shi Y,. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5 (11): 897-907.
64. Tait SW, Green DR,. Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 2010; 11 (9): 621-632.
65. Parrish AB, Freel CD, Kornbluth S,. Cellular mechanisms controlling caspase activation and function. Cold Spring Harb Perspect Biol 2013; 5 (6): a008672.
66. Taylor RC, Cullen SP, Martin SJ,. Apoptosis: Controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008; 9 (3): 231-241.
67. McCracken JM, Allen LA,. Regulation of human neutrophil apoptosis and lifespan in health and disease. J Cell Death 2014; 7: 15-23.
68. Jayakumar S, Kunwar A, Sandur SK, Pandey BN, Chaubey RC,. Differential response of DU145 and PC3 prostate cancer cells to ionizing radiation: Role of reactive oxygen species, GSH and Nrf2 in radiosensitivity. Biochim Biophys Acta 2014; 1840 (1): 485-494.
69. Lee JT Jr, Steelman LS, McCubrey JA,. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 2004; 64 (22): 8397-8404.
70. Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI,. Chemoresistance in prostate cancer cells is regulated by miRNAs and Hedgehog pathway. PLoS ONE 2012; 7 (6): e40021.
71. Shen T, Zhang L, Wang YY, Fan PH, Wang XN, Lin ZM, Lou HX,. Steroids from Commiphora mukul display antiproliferative effect against human prostate cancer PC3 cells via induction of apoptosis. Bioorg Med Chem Lett 2012; 22 (14): 4801-4806.
72. Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR,. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115 (4): 959-968.
73. Nasu Y, Timme TL, Yang G, Bangma CH, Li L, Ren C, Park SH, DeLeon M, Wang J, Thompson TC,. Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat Med 1998; 4 (9): 1062-1064.
74. Yang G, Truong LD, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC,. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4 (8): 1873-1880.
75. Nassar ZD, Hill MM, Parton RG, Parat MO,. Caveola-forming proteins caveolin-1 and PTRF in prostate cancer. Nat Rev Urol 2013; 10 (9): 529-536.
76. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M, Lisanti MP,. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: Genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 2005; 280 (26): 25134-25145.
77. Li L, Yang G, Ebara S, Satoh T, Nasu Y, Timme TL, Ren C, Wang J, Tahir SA, Thompson TC,. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61 (11): 4386-4392.
78. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN, Thompson TC,. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 2000; 19 (29): 3256-3265.
79. Segawa T, Nau ME, Xu LL, Chilukuri RN, Makarem M, Zhang W, Petrovics G, Sesterhenn IA, McLeod DG, Moul JW, Vahey M, Srivastava S,. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 2002; 21 (57): 8749-8758.
80. He JH, Zhang JZ, Han ZP, Wang L, Lv Y, Li YG,. Reciprocal regulation of PCGEM1 and miR-145 promote proliferation of LNCaP prostate cancer cells. J Exp Clin Cancer Res 2014; 33 (1): 72.
81. Yang L, Lin C, Jin C, Yang JC, Tanasa B, Li W, Merkurjev D, Ohgi KA, Meng D, Zhang J, Evans CP, Rosenfeld MG,. LncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013; 500 (7464): 598-602.
82. Pestell RG, Yu Z,. Long and noncoding RNAs (lnc-RNAs) determine androgen receptor dependent gene expression in prostate cancer growth in vivo. Asian J Androl 2014; 16 (2): 268-269.
83. Stone KR, Mickey DD, Wunderli H, Mickey GH, Paulson DF,. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978; 21 (3): 274-281.
84. Mitchell S, Abel P, Ware M, Stamp G, Lalani E,. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. BJU Int 2000; 85 (7): 932-944.
85. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW,. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979; 17 (1): 16-23.
86. Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R,. Androgen receptor expression in androgen-independent prostate cancer cell lines. Prostate 2001; 47 (1): 66-75.
87. Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ,. Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior. Prostate 1991; 18 (3): 201-214.